| Residential College | false |
| Status | 已發表Published |
| Development of GPC3-CAR-NK cells and optimization as a therapy for HCC | |
Cao, Bihui; Ni, Qianqian; Chen, Zhuxin; Yang, Shuo; Zhang, Xinkui; Su, Haotao; Zheng, Zhenfeng; Zhao, Qi  ; Zhu, Xiaolan; Liu, Manting
| |
| 2024-06-26 | |
| Source Publication | Journal of leukocyte biology
 |
| ISSN | 1938-3673 |
| Volume | 0Issue:0Pages:1-11 |
| Abstract | Hepatocellular carcinoma (HCC) is a highly malignant tumor characterized by insidious onset and rapid progression, with limited treatment choices. One treatment modality, chimeric antigen receptor (CAR)-modified natural killer (NK) cell immunotherapy, has shown promise for various cancers. In this study, we developed two GPC3-specific CAR-NK-92 cell lines (GPC3-CAR-NK) and explored their antitumor efficacy for the treatment of HCC. Significant levels of cytokine production and in vitro cytotoxicity were produced following co-culture of GPC3+ HCC cells with the developed GPC3-CAR-NK cells. GC33-G2D-NK cells with NK cell-specific signaling domains showed better activation and killing abilities than GC33-CD28-NK cells containing T cell-specific signaling domains. Moreover, GC33-G2D-NK cells efficiently eliminated tumors in cell-derived xenograft and patient-derived xenograft mouse models. In an abdominal metastasis model, intraperitoneally delivered GC33-G2D-NK cells showed better antitumor ability than intravenously injected cells. Finally, the combination of microwave ablation with GC33-G2D-NK cell administration showed greater CAR-NK infiltration and tumor regression in ablated tumors than monotherapy alone. These findings indicate that administration of GPC3-CAR-NK cells may be a potential strategy for the treatment of HCC, and regional delivery or their combination with microwave ablation may optimize their efficacy against HCC and may have translational value. |
| Keyword | Hcc Mwa Chimeric Antigen Receptor Glypican-3 Natural Killer. |
| DOI | 10.1093/jleuko/qiae144 |
| URL | View the original |
| Indexed By | SCIE |
| Fulltext Access | |
| Citation statistics | |
| Document Type | Journal article |
| Collection | DEPARTMENT OF BIOMEDICAL SCIENCES |
| Corresponding Author | Zhao, Qi; Zhu, Xiaolan; Liu, Manting |
| Affiliation | MoE Frontiers Science Center for Precision Oncology, Faculty of Health Sciences, University of Macau, Macau SAR, China |
| Recommended Citation GB/T 7714 | Cao, Bihui,Ni, Qianqian,Chen, Zhuxin,et al. Development of GPC3-CAR-NK cells and optimization as a therapy for HCC[J]. Journal of leukocyte biology, 2024, 0(0), 1-11. |
| APA | Cao, Bihui., Ni, Qianqian., Chen, Zhuxin., Yang, Shuo., Zhang, Xinkui., Su, Haotao., Zheng, Zhenfeng., Zhao, Qi., Zhu, Xiaolan., & Liu, Manting (2024). Development of GPC3-CAR-NK cells and optimization as a therapy for HCC. Journal of leukocyte biology, 0(0), 1-11. |
| MLA | Cao, Bihui,et al."Development of GPC3-CAR-NK cells and optimization as a therapy for HCC".Journal of leukocyte biology 0.0(2024):1-11. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment